Dose Modifications in Exposure-Response Analyses of Oncology Drug Development: Brigimadlin Case Study

ACoP16 (Oct 2025), Poster: M-115
Le Louedec F, Kang J, Sarr C, Neldemo I, Wiens M, Baron K, Lamar M, Pérez-Pitarch A, Schmid U, Sailer R, Bergstrand M, Busse D.
ConferenceMethodologyMIDDOncologyPBPK/PBBMPharmacometricsSpecial considerations

Pharmetheus Affiliates

Portrait-of-Felicien-Le-Louedec-Pharmetheus-1
Director, MIDD Consultant

Félicien Le Louedec

See bio
Portrait-of-Celine-Sarr_Pharmetheus
Principal Director, MIDD Consultant

Céline Sarr

See bio
Portrait-of-Ida-Neldemo_Pharmetheus
Senior Director, MIDD Consultant

Ida Neldemo

See bio
Portrait-of-Martin-Bergstrand_Pharmetheus
Principal Director, MIDD Scientific Lead

Martin Bergstrand

See bio